This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

JR-032

GlaxoSmithKline plc

Drug Names(s): iduronate-2-sulfatase, IDS

Description: JR-032 is an enzyme replacement therapy of rDNA origin in development for Hunter Syndrome. It is manufactured using serum-free culture technology.

Deal Structure: JR-032 was originally developed by JCR Pharmaceuticals.

In December 2009, GSK entered into an agreement with JCR Pharmaceuticals for the global rights to a number of enzyme replacement therapies to treat orphan diseases such as Hunter Syndrome, Fabry disease and Gaucher disease.

Partners: JCR Pharmaceuticals Co., Ltd.


JR-032 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug